Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.

The objective of this study was to determine if the addition of megestrol acetate (MA), a modulator of P-glycoprotein-mediated drug resistance, to first-line cytotoxic therapy in patients with limited and advanced stage small-cell lung cancer (SCLC) would improve median time to disease progression a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, L., Palmer, M., Hewitt, J., Urtasun, R., Bruera, E., Rapp, E., Thaell, J. F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149923/
https://www.ncbi.nlm.nih.gov/pubmed/9484821

Ejemplares similares

Ejemplares similares